Does Insurance Cover Wegovy in the UK?

Why most UK health insurance policies don't pay for Wegovy right now

The short answer is categorisation. Private health insurers in the UK have historically drawn a line between "medical" treatments and "lifestyle" ones, and weight management medicines have landed firmly in the second group for most providers. Wegovy is licensed for obesity (a recognised clinical condition) but insurers' policy documents have not always caught up with that framing. Standard exclusion clauses will typically list weight-loss drugs or treatments for obesity explicitly, and semaglutide falls under both.

There is also a cost argument that insurers make internally. Wegovy is taken indefinitely in many cases; the moment an insurer covers an ongoing medicine for a large proportion of its book, the actuarial numbers change sharply. That commercial pressure means blanket exclusions are easier to sustain than case-by-case approvals, even where a clinical case is clear. Some policies offer enhanced or executive health cover that is starting to include weight-management medicines, if you have a workplace policy, it genuinely is worth reading the small print or phoning the insurer directly. Policies vary more than people assume.

For a fuller breakdown of which insurers are reviewing their position, our guide to insurers that cover Wegovy covers the main providers and what their current position appears to be.

NHS cover for Wegovy: real, but tightly rationed

There is a publicly funded route to Wegovy. NICE recommended semaglutide (Wegovy) for NHS use in 2023 under TA875, but with strict conditions: it must be prescribed within a specialist weight management service, as part of a multidisciplinary programme, for a maximum of two years, and for adults with a BMI of 35 or above and at least one weight-related health condition. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

In practice, those specialist services have long waiting lists in most areas. Demand outstrips current capacity significantly. Meeting the NICE criteria does not translate to quick access; some patients wait a year or more for a first appointment. If you are referred by your GP, your local integrated care board determines which services are commissioned and when. Scotland, Wales and Northern Ireland operate under different frameworks with their own criteria.

The NHS route is real and worth pursuing if you meet the criteria. It is simply not fast, and it is not available through a GP prescribing independently in most areas. For people who do not qualify or do not want to wait, private treatment through a regulated online pharmacy is the practical alternative.

What paying privately actually involves, and what it costs

Private treatment for Wegovy means a prescription from a registered independent prescriber following a clinical consultation, dispensed through a GPhC-registered pharmacy. There is no insurance offsetting the cost; you pay the full amount, which varies by dose and provider. Since Novo Nordisk adjusted UK pricing in 2025, typical private costs across the market have ranged roughly £149 to £375 per month depending on the dose, those figures reflect widely reported market data and will vary between pharmacies.

Understanding what a given price includes matters. Some providers quote a headline pen price and bill separately for the consultation, the prescription, and delivery. Others include everything. Our Wegovy pricing guide explains the components to check when comparing options, so you're not caught out by fees that appear later. One thing to verify for any online pharmacy is their GPhC registration, you can check any registered pharmacy at the GPhC register.

It is also worth knowing that Wegovy's effects on metabolic health extend beyond the number on the scale. If you have prediabetes or metabolic syndrome alongside your weight, reading about whether Wegovy helps with insulin resistance may be relevant to your decision. A prescriber can assess whether those factors change the clinical picture for you.

Making the decision: NHS, insurer, or private route?

Most people reading this are trying to work out the most realistic path. Here is the honest shape of it. If you have a qualifying BMI and comorbidities, a GP referral to a specialist service is the right first step and costs nothing, but prepare for a wait. If you have private health insurance, checking which insurance companies cover Wegovy is a useful starting point before you call your insurer directly to ask whether GLP-1 medicines are covered or under review; some are. If neither route is viable or quick enough, a private prescription from a clinically rigorous pharmacy is a legal, regulated option that many people are using now.

Before the school run, before a commute, a quick consultation call or online form can start the clinical process the same day. The prescriber's review is what matters, and that is always done by a registered clinician, not automated software. It is also worth being aware that semaglutide tolerance is something a good prescriber will monitor over time, particularly as your dose increases, so ongoing clinical oversight matters as much as the initial assessment. If you're weighing up whether private treatment is right for you, starting a free consultation gives you a clinical view on suitability without any commitment. Our clinical team reviews every case personally, and you can read more about the clinical oversight we provide through our lead prescriber's profile. If you have questions before starting, our FAQs cover the most common ones.